TNFR 2 is a type I transmembrane glycoprotein that plays a vital role in regulating the immune system. It consists of approximately 439 to 461 amino acids and is associated with various inflammatory and autoimmune diseases. On the other hand, adalimumab is a well-established anti-rheumatic drug and monoclonal antibody that targets and inactivates tumor necrosis factor-α, a key driver of inflammation in diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Through phage display antibody library construction and screening technologies, Alpha Lifetech ensures the rapid discovery of high-affinity blocking antibodies.